{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T05:44:13Z","timestamp":1786167853229,"version":"build-2736575974"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012910","name":"National Defense Medical College","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012910","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Ophthalmol"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To evaluate the intraocular pressure (IOP)-lowering efficacy and treatment stability of ripasudil-brimonidine fixed-dose combination (RBFC) in patients with secondary glaucoma associated with uveitis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study design<\/jats:title>\n                    <jats:p>Single-center, retrospective study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Medical records of 50 eyes prescribed RBFC were reviewed and categorized into inflammatory ocular hypertension (OH;\n                      <jats:italic>n<\/jats:italic>\n                      = 19), steroid-induced OH (\n                      <jats:italic>n<\/jats:italic>\n                      = 18), and primary open-angle glaucoma (POAG;\n                      <jats:italic>n<\/jats:italic>\n                      = 13). Clinical parameters\u2014including IOP, visual acuity (VA), and medication score\u2014were assessed at baseline, the first follow-up, and the final visit.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In the inflammatory and steroid-induced OH groups, mean IOP decreased significantly from baseline and remained stable throughout the observation period (\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&lt; 0.001). VA was maintained with a slight, non-significant improvement, and medication scores remained stable, indicating sustained treatment efficacy without additional eye drops. One mild case of conjunctivitis occurred in the POAG group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>RBFC was associated with significant IOP reduction in eyes with uveitis-associated or steroid-induced OH, without compromising visual function. These findings suggest that RBFC may be a useful therapeutic option for inflammation-related secondary glaucoma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10384-026-01361-0","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T08:38:50Z","timestamp":1776847130000},"page":"949-956","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of ripasudil-brimonidine fixed-dose combination in secondary glaucoma associated with uveitis: a retrospective study"],"prefix":"10.1007","volume":"70","author":[{"given":"Kenji","family":"Miyao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaya","family":"Imazeki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Oyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsaku","family":"Nakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4913-7089","authenticated-orcid":false,"given":"Masaru","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"key":"1361_CR1","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","volume":"140","author":"DA Jabs","year":"2005","unstructured":"Jabs DA, Nussenblatt RB, Rosenbaum JT, Standardization of Uveitis Nomenclature Working Group. Standardization of uveitis nomenclature for reporting clinical data. results of the first international workshop. Am J Ophthalmol. 2005;140:509\u201316.","journal-title":"Am J Ophthalmol"},{"key":"1361_CR2","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1159\/000078612","volume":"218","author":"OM Durrani","year":"2004","unstructured":"Durrani OM, Meads CA, Murray PI. Uveitis: a potentially blinding disease. Ophthalmologica. 2004;218:223\u201336.","journal-title":"Ophthalmologica"},{"key":"1361_CR3","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1080\/09273948.2021.2017152","volume":"29","author":"ET Ec","year":"2021","unstructured":"Ec ET, Zierhut M. Vision loss in uveitis. Ocul Immunol Inflamm. 2021;29:1037\u20139.","journal-title":"Ocul Immunol Inflamm"},{"key":"1361_CR4","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1097\/01.ijg.0000146391.77618.d0","volume":"13","author":"P Neri","year":"2004","unstructured":"Neri P, Azuara-Blanco A, Forrester JV. Incidence of glaucoma in patients with uveitis. J Glaucoma. 2004;13:461\u20135.","journal-title":"J Glaucoma"},{"key":"1361_CR5","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1136\/bjophthalmol-2013-304416","volume":"98","author":"T Kanda","year":"2014","unstructured":"Kanda T, Shibata M, Taguchi M, Ishikawa S, Harimoto K, Takeuchi M. Prevalence and aetiology of ocular hypertension in acute and chronic uveitis. Br J Ophthalmol. 2014;98:932\u20136.","journal-title":"Br J Ophthalmol"},{"key":"1361_CR6","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/S0021-5155(02)00549-X","volume":"46","author":"T Takahashi","year":"2002","unstructured":"Takahashi T, Ohtani S, Miyata K, Miyata N, Shirato S, Mochizuki M. A clinical evaluation of uveitis-associated secondary glaucoma. Jpn J Ophthalmol. 2002;46:556\u201362.","journal-title":"Jpn J Ophthalmol"},{"key":"1361_CR7","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s10384-022-00970-9","volume":"67","author":"Y Kiuchi","year":"2023","unstructured":"Kiuchi Y, Inoue T, Shoji N, Nakamura M, Tanito M. The Japan Glaucoma Society guidelines for glaucoma 5th edition. Jpn J Ophthalmol. 2023;67:189\u2013254.","journal-title":"Jpn J Ophthalmol"},{"key":"1361_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13051185","volume":"13","author":"I Halkiadakis","year":"2024","unstructured":"Halkiadakis I, Konstantopoulou K, Tzimis V, Papadopoulos N, Chatzistefanou K, Markomichelakis NN. Update on diagnosis and treatment of uveitic glaucoma. J Clin Med. 2024;13:1185.","journal-title":"J Clin Med"},{"key":"1361_CR9","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.ajo.2013.05.016","volume":"156","author":"H Tanihara","year":"2013","unstructured":"Tanihara H, Inoue T, Yamamoto T, Kuwayama Y, Abe H, Araie M. Phase 2 randomized clinical study of a Rho kinase inhibitor, K-115, in primary open-angle glaucoma and ocular hypertension. Am J Ophthalmol. 2013;156:731\u20136.","journal-title":"Am J Ophthalmol"},{"key":"1361_CR10","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1111\/aos.12599","volume":"93","author":"H Tanihara","year":"2015","unstructured":"Tanihara H, Inoue T, Yamamoto T, Kuwayama Y, Abe H, Suganami H, et al. Intra-ocular pressure-lowering effects of a Rho kinase inhibitor, ripasudil (K-115), over 24 hours in primary open-angle glaucoma and ocular hypertension: a randomized, open-label, crossover study. Acta Ophthalmol. 2015;93:e254\u201360.","journal-title":"Acta Ophthalmol"},{"key":"1361_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.preteyeres.2013.05.002","volume":"37","author":"T Inoue","year":"2013","unstructured":"Inoue T, Tanihara H. Rho-associated kinase inhibitors: a novel glaucoma therapy. Prog Retin Eye Res. 2013;37:1\u201312.","journal-title":"Prog Retin Eye Res"},{"key":"1361_CR12","doi-asserted-by":"publisher","first-page":"5584","DOI":"10.1167\/iovs.17-22679","volume":"58","author":"T Uchida","year":"2017","unstructured":"Uchida T, Honjo M, Yamagishi R, Aihara M. The anti-inflammatory effect of ripasudil (k-115), a Rho kinase (ROCK) inhibitor, on endotoxin-induced uveitis in rats. Invest Ophthalmol Vis Sci. 2017;58:5584\u201393.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1361_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/bmjophth-2024-001981","volume":"10","author":"K Harimoto","year":"2025","unstructured":"Harimoto K, Nishio Y, Someya H, Sato T, Ito M, Takeuchi M. Anti-inflammatory actions of ripasudil ameliorate experimental autoimmune uveoretinitis in the acute phase. BMJ Open Ophthalmol. 2025;10:e001981.","journal-title":"BMJ Open Ophthalmol"},{"key":"1361_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-66928-4","volume":"10","author":"A Futakuchi","year":"2020","unstructured":"Futakuchi A, Morimoto T, Ikeda Y, Tanihara H, Inoue T, collaborators R-Ssg. Intraocular pressure-lowering effects of ripasudil in uveitic glaucoma, exfoliation glaucoma, and steroid-induced glaucoma patients: ROCK-S, a multicentre historical cohort study. Sci Rep. 2020;10:10308.","journal-title":"Sci Rep"},{"key":"1361_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0185305","volume":"12","author":"M Yasuda","year":"2017","unstructured":"Yasuda M, Takayama K, Kanda T, Taguchi M, Someya H, Takeuchi M. Comparison of intraocular pressure-lowering effects of ripasudil hydrochloride hydrate for inflammatory and corticosteroid-induced ocular hypertension. PLoS ONE. 2017;12:e0185305.","journal-title":"PLoS ONE"},{"key":"1361_CR16","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s00417-018-3933-9","volume":"256","author":"S Kusuhara","year":"2018","unstructured":"Kusuhara S, Katsuyama A, Matsumiya W, Nakamura M. Efficacy and safety of ripasudil, a Rho-associated kinase inhibitor, in eyes with uveitic glaucoma. Graefes Arch Clin Exp Ophthalmol. 2018;256:809\u201314.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1361_CR17","doi-asserted-by":"publisher","DOI":"10.2174\/18743641-v16-e2206201","author":"T Mimura","year":"2022","unstructured":"Mimura T, Noma H, Inoue Y, Kawashima M, Kitsu K, Mizota A. Early postoperative effect of ripasudil hydrochloride after trabeculectomy on secondary glaucoma: a randomized controlled trial. Open Ophthalmol J. 2022. https:\/\/doi.org\/10.2174\/18743641-v16-e2206201.","journal-title":"Open Ophthalmol J"},{"key":"1361_CR18","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1097\/IJG.0000000000000051","volume":"23","author":"S Fan","year":"2014","unstructured":"Fan S, Agrawal A, Gulati V, Neely DG, Toris CB. Daytime and nighttime effects of brimonidine on IOP and aqueous humor dynamics in participants with ocular hypertension. J Glaucoma. 2014;23:276\u201381.","journal-title":"J Glaucoma"},{"key":"1361_CR19","doi-asserted-by":"publisher","first-page":"337","DOI":"10.2147\/tcrm.2006.2.4.337","volume":"2","author":"LB Cantor","year":"2006","unstructured":"Cantor LB. Brimonidine in the treatment of glaucoma and ocular hypertension. Ther Clin Risk Manag. 2006;2:337\u201346.","journal-title":"Ther Clin Risk Manag"},{"key":"1361_CR20","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1001\/archopht.1995.01100120044006","volume":"113","author":"CB Toris","year":"1995","unstructured":"Toris CB, Gleason ML, Camras CB, Yablonski ME. Effects of brimonidine on aqueous humor dynamics in human eyes. Arch Ophthalmol. 1995;113:1514\u20137.","journal-title":"Arch Ophthalmol"},{"key":"1361_CR21","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1177\/0960327120918307","volume":"39","author":"N Cimolai","year":"2020","unstructured":"Cimolai N. A review of neuropsychiatric adverse events from topical ophthalmic brimonidine. Hum Exp Toxicol. 2020;39:1279\u201390.","journal-title":"Hum Exp Toxicol"},{"key":"1361_CR22","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1007\/s00417-024-06388-y","volume":"262","author":"H Tanihara","year":"2024","unstructured":"Tanihara H, Yamamoto T, Aihara M, Koizumi N, Fukushima A, Kawakita K, et al. Long-term intraocular pressure-lowering efficacy and safety of ripasudil-brimonidine fixed-dose combination for glaucoma and ocular hypertension: a multicentre, open-label, phase 3 study. Graefes Arch Clin Exp Ophthalmol. 2024;262:2579\u201391.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1361_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13144158","volume":"13","author":"H Onoe","year":"2024","unstructured":"Onoe H, Hirooka K, Baba T, Nagayama M, Hirota A, Suzuki K, et al. The efficacy and safety associated with switching from concomitant brimonidine and ripasudil, or brimonidine or ripasudil monotherapy to a fixed combination of brimonidine and ripasudil in glaucoma patients. J Clin Med. 2024;13:4158.","journal-title":"J Clin Med"},{"key":"1361_CR24","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1136\/bjophthalmol-2016-308505","volume":"101","author":"CY Kim","year":"2017","unstructured":"Kim CY, Park KH, Ahn J, Ahn MD, Cha SC, Kim HS, et al. Treatment patterns and medication adherence of patients with glaucoma in South Korea. Br J Ophthalmol. 2017;101:801\u20137.","journal-title":"Br J Ophthalmol"},{"key":"1361_CR25","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/s10384-025-01243-x","volume":"69","author":"R Yamagishi-Kimura","year":"2025","unstructured":"Yamagishi-Kimura R, Honjo M, Aihara M. Neuroprotective effect of ripasudil on retinal ganglion cells via an antioxidative mechanism. Jpn J Ophthalmol. 2025;69:823\u201332.","journal-title":"Jpn J Ophthalmol"},{"key":"1361_CR26","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1186\/s12886-020-01762-w","volume":"20","author":"S Hopf","year":"2020","unstructured":"Hopf S, Mercieca K, Pfeiffer N, Prokosch-Willing V. Brimonidine-associated uveitis - a descriptive case series. BMC Ophthalmol. 2020;20:489.","journal-title":"BMC Ophthalmol"},{"key":"1361_CR27","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1007\/s00417-013-2415-3","volume":"251","author":"A Casado","year":"2013","unstructured":"Casado A, Cabarga C, de la Fuente MA, Mu\u00f1oz-Negrete FJ. Suspected granulomatous anterior uveitis associated with brimonidine tartrate 0.2% and timolol maleate 0.5% ophthalmic solution. Graefes Arch Clin Exp Ophthalmol. 2013;251:2659\u201360.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1361_CR28","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/S0002-9394(00)00491-8","volume":"130","author":"DB Byles","year":"2000","unstructured":"Byles DB, Frith P, Salmon JF. Anterior uveitis as a side effect of topical brimonidine. Am J Ophthalmol. 2000;130:287\u201391.","journal-title":"Am J Ophthalmol"},{"key":"1361_CR29","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3109\/09273948.2015.1037845","volume":"24","author":"J Beltz","year":"2016","unstructured":"Beltz J, Zamir E. Brimonidine induced anterior uveitis. Ocul Immunol Inflamm. 2016;24:128\u201333.","journal-title":"Ocul Immunol Inflamm"}],"container-title":["Japanese Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-026-01361-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10384-026-01361-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-026-01361-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T05:22:55Z","timestamp":1786166575000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10384-026-01361-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1361"],"URL":"https:\/\/doi.org\/10.1007\/s10384-026-01361-0","relation":{},"ISSN":["0021-5155","1613-2246"],"issn-type":[{"value":"0021-5155","type":"print"},{"value":"1613-2246","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]},"assertion":[{"value":"6 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K. Miyao, None; M. Imazeki, None; T. Oyama, None; S. Nakai, None; T. Kanda, None; M.Takeuchi, None.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}